{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(9)"],"submitter":["Kassir N"],"pubmed_abstract":["Etrolizumab is an IgG1-humanized monoclonal anti-β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately-to-severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibitors (HICKORY) or were TNF inhibitor naïve (HIBISCUS I/II, LAUREL, and GARDENIA). A total of eight exposure-response analyses were conducted for two clinical outcomes (remission and endoscopic improvement) at the end of induction for studies HIBISCUS I/II (combined) and HICKORY and at the end of maintenance for studies HICKORY and LAUREL. Trough concentration at week 4 (C<sub>trough,wk4</sub> ) of induction was selected as the exposure metric. Exposure-response (ER) modeling was conducted using logistic re"],"journal":["CPT: pharmacometrics & systems pharmacology"],"pagination":["1234-1243"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9469693"],"repository":["biostudies-literature"],"pubmed_title":["Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis."],"pmcid":["PMC9469693"],"pubmed_authors":["Zhang W","Moein A","Oh YS","Langenhorst J","Kassir N","Ribbing J","Zhu R","Zhang R","Tang MT"],"additional_accession":[]},"is_claimable":false,"name":"Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis.","description":"Etrolizumab is an IgG1-humanized monoclonal anti-β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately-to-severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibitors (HICKORY) or were TNF inhibitor naïve (HIBISCUS I/II, LAUREL, and GARDENIA). A total of eight exposure-response analyses were conducted for two clinical outcomes (remission and endoscopic improvement) at the end of induction for studies HIBISCUS I/II (combined) and HICKORY and at the end of maintenance for studies HICKORY and LAUREL. Trough concentration at week 4 (C<sub>trough,wk4</sub> ) of induction was selected as the exposure metric. Exposure-response (ER) modeling was conducted using logistic re","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-05T10:46:03.563Z","creation":"2025-04-05T10:46:03.563Z"},"accession":"S-EPMC9469693","cross_references":{"pubmed":["35789549"],"doi":["10.1002/psp4.12840"]}}